A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients

We wanted to examine tolerability and efficacy of NSI-189, a benzylpiperizine-aminiopyridine neurogenic compound for treating major depressive disorder (MDD). This was a Phase 1B, double blind, randomized, placebo controlled, multiple-dose study with three cohorts. The first cohort received 40 mg q....

Descripción completa

Detalles Bibliográficos
Autores principales: Fava, M, Johe, K, Ereshefsky, L, Gertsik, L G, English, B A, Bilello, J A, Thurmond, L M, Johnstone, J, Dickerson, B C, Makris, N, Hoeppner, B B, Flynn, M, Mischoulon, D, Kinrys, G, Freeman, M P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5030464/
https://www.ncbi.nlm.nih.gov/pubmed/26643541
http://dx.doi.org/10.1038/mp.2015.178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5030464/
https://www.ncbi.nlm.nih.gov/pubmed/26643541
http://dx.doi.org/10.1038/mp.2015.178

Ejemplares similares